The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 50
- Locations
- 2
- Primary Endpoint
- Quality of Life Assessment with St George's Respiratory Questionnaire(SGRQ) and Leicester Cough Questionnaire(LCQ)
Study Overview
Brief Summary
The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.
Detailed Description
Non-cystic fibrosis bronchiectasis is an orphan disease caused by the pathogenic vicious circle including infection, inflammation and airway repair. Today's principle of treatment is to break the cycle of inflammation and infection. Nowadays, most clinical trials are anti-infective treatment by antibiotics trying to break this cycle by reducing the bacterial load, which may cause bacterial resistance. There were still some anti-inflammation trials by using inhaled corticosteroids(ICS). Tsang and Martínez-García showed that inhaled corticosteroids reduced IL-1,IL-8 levels and sputum inflammation cells, and improved sputum volume as well as quality of life, though the corticosteroid must be high dose or medium dose combined with long-acting ß2 adrenergic agonists. As described in asthma and chronic obstructive pulmonary disease(COPD), theophylline can improve the activity of histone deacetylase (HDAC) and then enhanced the anti-inflammatory effect of steroids. We hypothesis that theophylline may have the same effect in subjects with bronchiectasis. Theophylline plus inhaled low-dose formoterol-budesonide may improve quality of life and reduce airway inflammation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients between 18-70 years old with non-cystic fibrosis(CF) bronchiectasis, free from acute exacerbations for at least 3 months.Stable phase of the disease.
Exclusion Criteria
- •Patients with a cigarette smoking history of more than 10 packs-year. Patients with COPD. Patients with traction bronchiectasis due to advanced fibrosis. Patients with known intolerance for theophylline. Patients with asthma. Patients with other disease disturbing outcomes of the trials. Patients without consent.
Arms & Interventions
Placebo+formoterol-budesonide
Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.
Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks.
Intervention: Formoterol-budesonide (Drug)
Placebo+formoterol-budesonide
Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.
Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks.
Intervention: Placebo (Drug)
Theophylline+formoterol-budesonide
Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.
Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks.
Intervention: Formoterol-budesonide (Drug)
Theophylline+formoterol-budesonide
Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.
Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks.
Intervention: Theophylline (Drug)
Outcomes
Primary Outcomes
Quality of Life Assessment with St George's Respiratory Questionnaire(SGRQ) and Leicester Cough Questionnaire(LCQ)
Time Frame: Baseline and 24 weeks
Secondary Outcomes
- Changes of sputum characteristics from baseline to 24 weeks(Baseline and 24 weeks)
- Changes of 24 hour sputum volume from baseline to 24 weeks(Baseline and 24 weeks)
- Changes of forced expiratory volume in 1 second(FEV1) from baseline to 24 weeks(Baseline and 24 weeks)
- Changes of mean forced expiratory flow between 25% and 75% of the FVC(FEF25-75)from baseline to 24 weeks(Baseline and 24 weeks)
- Changes of forced vital capacity(FVC) from baseline to 24 weeks(Baseline and 24 weeks)
- Mean number of exacerbations per patient per 24 weeks(Baseline and 24 weeks)
- Changes of peak expiratory flow(PEF) from baseline to 24 weeks(Baseline and 24 weeks)
- Induced sputum cytology count(Baseline and 24 weeks)
- Changes of sputum culture from baseline to 24 weeks(Baseline and 24 weeks)
- IL-6(Baseline and 24 weeks)
- IL-8(Baseline and 24 weeks)
- IL-10(At 24 weeks)
- Tumor necrosis factor(TNF)α(Baseline and 24 weeks)
- Activity of histone deacetylase(HDAC)(Baseline and 24 weeks)
- Activity of histone acetyltransferase(HAT)(Baseline and 24 weeks)
- 8-Isoprostane(Baseline and 24 weeks)
- Neutrophilic granulocytes in blood routine examination(Baseline and 24 weeks)
- White blood cells in blood routine examination(Baseline and 24 weeks)
- Monocytes in blood routine examination(Baseline and 24 weeks)
- Eosinophilic granulocytes in blood routine examination(Baseline and 24 weeks)
- Number of participants with Adverse events as a measure of safety and tolerability(24 weeks)
- Plasma Concentration of Theophylline(24 weeks)
Investigators
Xugang
Medical Doctor
The First Affiliated Hospital of Guangzhou Medical University